Catalyst Wire Dossier Catalyst Wire Dossier

BGB-30813

BGB-30813 · BeiGene
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BGB-30813, covering 2025-09-16 to 2025-09-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors [Phase 1]

See pricing